ANTIGENIC VARIATION AND SEROTYPING OF HIV TYPE-1 FROM 4 WORLD-HEALTH-ORGANIZATION-SPONSORED HIV VACCINE SITES

Authors
PAU CP KAI M HOLLOMANCANDAL DL LUO CC KALISH ML SCHOCHETMAN G BYERS B GEORGE JR OSMANOV S BELSEY EM HEYWARD W ESPARZA J GALVAOCASTRO B VANDEPERRE P KARITA E WASI C SEMPALA S TUGUME B BIRYAHWAHO B RUBSAMENWAIGMANN H VONBRIESEN H ESSER R GREZ M HOLMES H NEWBERRY A RANJBAR S TOMLINSON P BRADAC J MCCUTCHAN F LOUWAGIE J HEGERICH P LOPEZGALINDEZ C OLIVARES I DOPAZO J MULLINS JI DELWART EL BACHMANN HM GOUDSMIT J DEWOLF F HAHN BH GAO F YUE L SARAGOSTI S KALISH M GEORGE R WEBER J CHEINGSONGPOPOV R KALEEBU P NARA P FENYO EM ALBERT J MYERS G KORBER B
Citation
Cp. Pau et al., ANTIGENIC VARIATION AND SEROTYPING OF HIV TYPE-1 FROM 4 WORLD-HEALTH-ORGANIZATION-SPONSORED HIV VACCINE SITES, AIDS research and human retroviruses, 10(11), 1994, pp. 1369-1377
Citations number
12
Categorie Soggetti
Immunology,"Infectious Diseases
Journal title
AIDS research and human retroviruses → ACNP
ISSN journal
08892229
Volume
10
Issue
11
Year of publication
1994
Pages
1369 - 1377
Database
ISI
SICI code
0889-2229(1994)10:11<1369:AVASOH>2.0.ZU;2-R
Abstract
Serologic reactivities of serum or plasma from 55 HIV-1 subjects in fo ur countries-Brazil, Rwanda, Thailand, and Uganda-were examined by V3 peptide immunoassay. Forty-seven (85.5%) of the 55 specimens tested po sitive to the homologous peptide. A strong correlation between serotyp e (i.e., pattern of serologic reactivity with a panel of peptides) and genotype was not found. However, the V3 peptide immunoassays may be u seful for epidemiologic studies to trace the distinctive HIV-1 strains from different geographic regions of the world. The serology data obt ained may be useful for the development of effective V3-based vaccines .